Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 13/20 | 0.67 |
| ▸ | CDC25B | P30305 | 4/20 | 0.40 |
| ▸ | CDC25A | P30304 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.35 |
| ▸ | S100A4 | P26447 | 2/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14135227 | 1.00 | APEX1 (0.67) | APEX1CDC25BCDC25APKMMAP2K7 | |
| SCHEMBL15705620 | 0.89 | APEX1 (0.59) | APEX1CDC25BCDC25AMAP2K7TDP2 | |
| SCHEMBL15711188 | 0.88 | APEX1 (0.53) | APEX1CDC25BCDC25APKMMAP2K7 | |
| SCHEMBL17834000 | 0.87 | APEX1 (0.54) | APEX1TDP2PAX8HKDC1TLR9 | |
| SCHEMBL14135167 | 0.87 | APEX1 (0.52) | APEX1CDC25BCDC25APKMMAP2K7 | |
| SCHEMBL19500018 | 0.87 | APEX1 (0.52) | APEX1CDC25BCDC25APKMMAP2K7 | |
| SCHEMBL15711189 | 0.86 | APEX1 (0.64) | APEX1CDC25BCDC25AMAP2K7 | |
| SCHEMBL17835128 | 0.85 | APEX1 (0.60) | APEX1CDC25BCDC25AMAP2K7 | |
| SCHEMBL15705622 | 0.85 | APEX1 (0.60) | APEX1CDC25BCDC25AMAP2K7 | |
| SCHEMBL17689686 | 0.85 | APEX1 (0.90) | APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-07-09 | — | — | US | disclosed |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIV AND RES TECH CORP (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIV AND RES TECH CORP (US) | 2017-10-26 | — | — | US | disclosed |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIVERSITY AND RES TECHNOLOGY CORP (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | OGG1, UNG, ERCC4 | APEX1 12/4885CDC25B 1413/4885CDC25A 1563/4885 |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | APEX1 12/4885CDC25B 1413/4885CDC25A 1563/4885 |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | APEX1 12/4885CDC25B 1281/4885CDC25A 1450/4885 |
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | OGG1, UNG, ERCC4 | APEX1 12/4885CDC25B 1413/4885CDC25A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.